Patients diagnosed with pheochromocytoma or paraganglioma ... the disease is localized and can be effectively removed in surgery. However, between 15 and 20% of patients are diagnosed after ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.